UGT8 and breast carcinoma: found that zoledronic acid, a direct inhibitor of UGT8, effectively blocked the production of two downstream metabolites in the thiosemicarbazone biosynthetic pathway in a concentration-dependent manner, while significantly inhibiting the migration and invasion of breast cancer cells.